<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Procedural sedation in children: Selection of medications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Procedural sedation in children: Selection of medications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Procedural sedation in children: Selection of medications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph P Cravero, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark G Roback, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne M Stack, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrienne G Randolph, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2258654">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will discuss the selection of medications for emergency and scheduled (elective) pediatric procedural sedation. The properties of agents commonly used for procedural sedation in children; the assessment, preparation, and proper performance of pediatric procedural sedation in children are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2927987530">
         <span class="h1">
          TOPIC SCOPE
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic provides guidance for emergency and scheduled (elective) pediatric procedural sedation performed by sedation providers from a variety of disciplines including general and pediatric emergency medicine, pediatric critical care medicine, pediatric hospital medicine, and general pediatrics.
        </p>
        <p>
         Recommendations for procedural sedation in children undergoing gastrointestinal endoscopy, bronchoscopy, cardiac catheterization, or interventional radiology are beyond the scope of this topic.
        </p>
        <p class="headingAnchor" id="H6054074">
         <span class="h1">
          NONPHARMACOLOGIC INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonpharmacologic interventions include behavioral and cognitive approaches, such as desensitization, distraction, reinforcement of coping skills, positive reinforcement, and relaxation. These techniques are complementary to pharmacologic interventions and, in some children, may prevent the need for sedation altogether. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253043">
         <span class="h1">
          CHOICE OF SEDATIVE AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The targeted depth of sedation and the agents used largely depend upon the anticipated degree of pain, the allowable amount of motion during the procedure, and the following patient factors [
         <a href="#rid1">
          1,2
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation", section on 'Pre-sedation evaluation'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbidities (eg, asthma, upper respiratory tract infection)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fasting status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age and development level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to cooperate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Degree of anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any prior problems with specific medications
        </p>
        <p>
        </p>
        <p>
         The dosing, administration, and properties of commonly used medications for pediatric sedation are listed in the tables and discussed in detail separately  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents"
         </a>
         .)
        </p>
        <p>
         In some facilities, the use of specific sedatives may be restricted to use by anesthesiologists or other specialists (eg, pediatric critical care or pediatric emergency medicine specialists). For example, in some settings,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         is
         <strong>
          only
         </strong>
         approved for use by anesthesiologists or others with specialized pediatric procedural sedation training. Otherwise, bolus propofol use for procedural sedation in children requires special privileging. The clinician should be aware of local requirements.
        </p>
        <p class="headingAnchor" id="H864250452">
         <span class="h2">
          Safety requirements
         </span>
         <span class="headingEndMark">
          —
         </span>
         Safe use of sedative agents outside of the operating room requires careful attention to the following factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selection and preparation of patients
         </strong>
         – The patient should be evaluated and prepared for sedation in accordance with guidelines designed to maximize patient safety. This assessment, includes an American Society of Anesthesiologists (ASA) physical status classification  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) and helps to identify patients at higher than normal risk for sedation. (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation", section on 'Pre-sedation evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation", section on 'Preparation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Those patients with ASA class IV, and V, functional needs, or airway abnormalities warrant consultation with a pediatric anesthesiologist. These patients are at increased risk for sedation-related adverse events and should be cared for by individuals who are specifically trained and experienced with high-risk pediatric procedural sedation. For elective procedures, high-risk patients should ideally receive sedation in an organized pediatric sedation service that has ancillary personnel with sedation expertise and an ongoing quality improvement program.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Competency of the sedation provider
         </strong>
         – Health care providers who perform procedural sedation in children should have strong resuscitation and advanced pediatric life support skills, including advanced training in the assessment and management of the pediatric airway as well as specific training in pediatric procedural sedation. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Performing procedural sedation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Institutional oversight
         </strong>
         – Institutions should develop guidelines and requirements that support the safe practice of pediatric sedation, including credentialing of individual providers and measurement and assessment of the quality of sedation care. In settings where pediatric procedural sedation is routine (eg, children's hospitals), a pediatric sedation service can provide efficient and effective sedation and is a systematic support for the safe performance of sedation. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Adverse outcomes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2253050">
         <span class="h1">
          SEDATION FOR IMAGING STUDIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging can often be performed
         <strong>
          without
         </strong>
         sedation in older cooperative children and young infants (up to six months of age) who are bundled and recently fed. Furthermore, as newer technologies decrease the image capture time for computed tomography (CT), some younger infants and many uncooperative patients can be imaged
         <strong>
          without
         </strong>
         sedation [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         However, a significant number of older infants, toddlers, and older children with intellectual disability cannot cooperate even for brief imaging tests (eg, helical CT) and warrant sedation to ensure accurate imaging without excessive radiation exposure. Thus, imaging tests that are negatively impacted by motion (eg, noninterventional CT or magnetic resonance imaging [MRI]) constitute the most common nonpainful procedures for which children undergo sedation [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Ideally, the chosen agent or agents should have a quick onset of action that permits successful and safe completion of the imaging study, maintains airway reflexes, and has limited impact on breathing and hemodynamic stability [
         <a href="#rid5">
          5
         </a>
         ]. The regimen should also permit rapid recovery with few side effects, such as nausea or agitation. Because imaging studies are not painful, analgesia is
         <strong>
          not
         </strong>
         necessary.
        </p>
        <p>
         Anesthesia for children undergoing MRI or CT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91608.html" rel="external">
          "Anesthesia for magnetic resonance imaging and computed tomography procedures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253057">
         <span class="h2">
          Computed tomography
         </span>
        </p>
        <p class="headingAnchor" id="H3100661883">
         <span class="h3">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Successful imaging with helical CT is less sensitive to patient movement than MRI and, given the rapid speed of imaging, can frequently be done without sedation or requires only brief sedation (approximately 5 to 10 minutes). As an example, in one case series of 104 patients undergoing helical CT, only 9 percent received sedation [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         When sedation is required, the clinician has a choice of several different agents as discussed below.
        </p>
        <p>
         The intravenous (IV) route is preferred where maximal efficiency and throughput is desirable, such as patients undergoing urgent imaging for diagnostic purposes, because the onset of action is shorter and more predictable, titration is easier, and (depending upon the agent), recovery is quicker  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Intravenous medications'
         </a>
         below.)
        </p>
        <p>
         Other routes of administration are feasible for children without IV access, especially in settings where CT imaging is elective and longer sedation duration and recovery times are acceptable  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). However, if inadequate sedation or serious adverse events occur, lack of IV access may impede further management [
         <a href="#rid7">
          7
         </a>
         ]. Thus, we prefer to provide IV sedation whenever possible. (See
         <a class="local">
          'No intravenous access'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2253064">
         <span class="h3">
          Intravenous medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that healthy infants and children (American Society of Anesthesiologists [ASA] class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) who have vascular access and are undergoing sedation for CT receive IV
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         rather than IV short-acting barbiturates (eg,
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) or
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Evidence identifying the best sedative agent for children undergoing CT is limited. Based upon observational studies, IV
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         is associated with effective sedation in over 99 percent of children undergoing CT compared with 97 to 98 percent of children receiving short-acting barbiturates or
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5,8-12
         </a>
         ]. Although lower efficacy was described for IV etomidate (76 percent of 17 patients) in one small trial, more than 99 percent of 446 children receiving etomidate for imaging successfully completed the procedure in a subsequent observational study [
         <a href="#rid8">
          8,9,13
         </a>
         ]. Based upon a review of prospectively collected registry data from over 22,000 children, IV
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         is also frequently used for imaging; radiologic procedures accounted for almost 25 percent of reported use in the study [
         <a href="#rid13">
          13
         </a>
         ]. Although not specifically reported for radiologic procedures, 99.8 percent of all procedures were successfully completed which suggests that IV ketamine has similar efficacy for CT when compared with propofol, etomidate, or dexmedetomidine. However, when used as a single agent, ketamine may be associated with random movement in some patients and may not be ideal.
        </p>
        <p>
         IV
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         have a more rapid onset of action than
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         (1 to 2 minutes versus 8 to 16 minutes, respectively) and etomidate has a shorter duration of action than dexmedetomidine (approximately 15 minutes compared with 30 minutes, respectively) [
         <a href="#rid8">
          8-12
         </a>
         ]. Duration of action with ketamine and propofol varies by dose and mode of administration (bolus or continuous infusion) and compares favorably with etomidate.
        </p>
        <p>
         Evidence is lacking to suggest that
         <strong>
          major
         </strong>
         adverse events (eg, laryngospasm, aspiration, apnea requiring airway intervention, or need for resuscitation) varies by the medication used to sedate for CT. Adverse events that are not necessarily life-threatening have been described in 2 percent of infants and children receiving
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         sedation for imaging and 1 percent receiving
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         . By contrast, approximately 5 percent of patients receiving IV short-acting barbiturates (eg,
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) and up to 7 percent receiving IV
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         experience adverse events, primarily respiratory depression with transient oxygen desaturation [
         <a href="#rid8">
          8,10,14
         </a>
         ]. Less commonly apnea has been described, especially in patients receiving short-acting barbiturates.
        </p>
        <p>
         Other adverse reactions that are specific to the agent are described in the table  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Sedative-hypnotic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253072">
         <span class="h3">
          No intravenous access
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer administration of IV medications, whenever possible, for uncooperative children undergoing CT. (See
         <a class="local">
          'Intravenous medications'
         </a>
         above.)
        </p>
        <p>
         When an IV cannot be placed, medication options and route of administration include  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral or intranasal (IN)
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intramuscular (IM)
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         by the oral or IN route achieves successful minimal sedation in 50 to 87 percent of patients undergoing CT, with higher efficacy when delivered IN [
         <a href="#rid15">
          15-17
         </a>
         ]. Onset of sedation is more rapid when midazolam is administered IN (generally, less than 10 minutes) [
         <a href="#rid18">
          18
         </a>
         ], while oral midazolam takes approximately 30 minutes [
         <a href="#rid19">
          19
         </a>
         ]. IM
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         may be preferred when timely imaging is necessary. Dissociative sedation with IM ketamine is associated with more adverse events and serious adverse events than minimal sedation with midazolam or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         . Furthermore, random motion may occur during ketamine sedation which can impair successful completion of the study. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
         Limited evidence from two randomized trials suggests that IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         produces adequate sedation in 60 to 74 percent of children undergoing CT. The onset of sedation (approximately 30 minutes) and time to discharge (approximately 40 minutes) appears similar to oral
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid20">
          20,21
         </a>
         ]. Further study is needed to determine the optimal dosing for intranasal dexmedetomidine.
        </p>
        <p>
         Regardless of agent and route chosen, children should undergo monitoring of oxygen saturation and heart rate according to recommendations because the risk of adverse events is significant regardless of the route of administration. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Monitoring'
         </a>
         .)
        </p>
        <p>
         Despite their relatively high efficacy when compared with oral or intranasal
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or intranasal
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         , we do not endorse the use of oral or rectal short-acting barbiturates (eg,
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) because of their long duration of sedation relative to the short imaging time, high rates of adverse events during sedation, and potential for delayed adverse events, including prolonged sleepiness and ataxia [
         <a href="#rid15">
          15-17,22-27
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13143" href="/z/d/drug information/13143.html" rel="external">
          Chloral hydrate
         </a>
         is no longer recommended for sedation in children and is not available in many countries, including the United States. Some countries have removed chloral hydrate from national health formularies because of potential carcinogenicity although the risk of cancer from a single dose is inconclusive [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2253079">
         <span class="h2">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI often necessitates sedation for up to one hour. Furthermore, machine noise and lack of patient access pose additional challenges to achieving safe and effective sedation. We suggest that healthy infants and children (ASA class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) undergoing MRI receive sedation using
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         and dexmedetomidine, or dexmedetomidine bolus followed by propofol sedation  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ). Because it has a shorter time to recovery and discharge [
         <a href="#rid30">
          30
         </a>
         ], experienced providers often administer propofol given as a bolus of 2 to 4 mg/kg followed by an infusion at 150 to 200 mcg/kg/minute. The use of dexmedetomidine reduces the dose of propofol during sedation. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         may also be preferred in children with increases in pulmonary artery pressure, decreases in cardiac output, children with AV node conduction delay, or those receiving
         <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">
          digoxin
         </a>
         , beta blockers or other medications that slow AV node conduction.
        </p>
        <p>
         For some providers,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         may be preferred to
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         for sedation of children with sleep apnea. As an example, in an observational study of 82 children undergoing MRI sleep studies, dexmedetomidine provided an acceptable level of anesthesia with fewer patients requiring an artificial airway compared with propofol (13 versus 30 percent) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Sedation with continuous infusion of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         permits successful completion of MRI in approximately 97 to 99 percent of children when administered by experienced practitioners [
         <a href="#rid12">
          12,30,32-34
         </a>
         ]. Time to sedation is longer with dexmedetomidine than with propofol (10 versus &lt;1 minutes, respectively) [
         <a href="#rid12">
          12,30,32,33
         </a>
         ]. Recovery is typically complete 20 to 30 minutes after stopping a propofol infusion and 25 to 40 minutes after ending a dexmedetomidine infusion [
         <a href="#rid12">
          12,30,32,33,35,36
         </a>
         ].
        </p>
        <p>
         However, to achieve this level of success with
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         alone sometimes requires bolus dosing that exceeds current manufacturer recommendations  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ]. Alternatively, co-administration of
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         can permit effective sedation at lower doses of dexmedetomidine. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
         Either
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         can be used safely for MRI sedation, propofol may cause more need for airway intervention or IV fluid administration. Dexmedetomidine can be associated with marked bradycardia. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Propofol'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
         Evidence from observational studies supports the combination of moderate-dose
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         1 mcg/kg with low-dose
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         infusion for MRI sedation. The combination appears effective and with fewer adverse effects than propofol used alone. However, a large randomized trial is needed to confirm these findings [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         Although
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         by the oral or IV route was used in the past to sedate children undergoing MRI, the potential for adverse events may be increased and recovery time tends to be longer with a high rate of delirium during emergence when compared with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         infusion  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid23">
          23,39-42
         </a>
         ].
        </p>
        <p>
         Proper administration, dosing, adverse effects, contraindications, and precautions for
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Sedative-hypnotic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253087">
         <span class="h1">
          SEDATION FOR OTHER NONPAINFUL PROCEDURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some children, physical examination (eg, genital examination to document sexual assault or routine physical examination in children with intellectual disability) or other nonpainful procedures (eg, echocardiography or electroencephalogram) can cause anxiety and lack of cooperation with the medical provider. In many situations, nonpharmacologic interventions can permit completion of the examination or test. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'
         </a>
         .)
        </p>
        <p>
         When nonpharmacologic interventions are
         <strong>
          not
         </strong>
         sufficient and mild sedation is necessary for nonpainful procedures, we suggest that healthy children (American Society of Anesthesiologists class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) receive sedation with oral, sublingual (SL), or intranasal (IN)
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         rather than short-acting barbiturates  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). Inhaled
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         is also a reasonable option, although use of a nasal or face mask can be challenging in selected patients. In addition, a combination of IN
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         and dexmedetomidine or "ketodex" (1 mg/kg ketamine and 2 mcg/kg dexmedetomidine) shows promise for sedation, at least for nonpainful procedures. For example, in two large, retrospective observational studies, this combination had a success rate of 93 to 96 percent for sedation of children undergoing nonpainful procedures [
         <a href="#rid43">
          43,44
         </a>
         ]. However, further study comparing this combination with midazolam or dexmedetomidine alone, as described above, is warranted before use is routine.
        </p>
        <p>
         Intravenous (IV) sedation as described for CT is suggested for patients who fail
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         sedation by the routes described above. (See
         <a class="local">
          'Computed tomography'
         </a>
         above.)
        </p>
        <p>
         Multiple trials describe acceptable efficacy for pediatric sedation with IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         for pediatric sedation that appears equivalent or superior to oral
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , depending upon the procedure [
         <a href="#rid45">
          45-49
         </a>
         ]. In a systematic review of 12 trials that compared IN dexmedetomidine with other sedatives for nonpainful procedures, dexmedetomidine provided adequate sedation, according to validated sedation instruments, for 86 percent of 1021 children compared with 77 percent of 277 children receiving other types of sedation (eg, IN or oral midazolam or oral
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         ) and was similar to IN midazolam in two trials [
         <a href="#rid49">
          49
         </a>
         ]. Adverse effects after IN dexmedetomidine administered in doses ranging from 1 to 4 mcg/kg included bradycardia (2.2 percent), hypotension (1.2 percent), oxygen desaturation (0.5 percent), and vomiting (0.4 percent); none required advanced life support.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         has both anxiolytic and amnestic properties. After oral or SL administration, it has an onset of action of 5 to 10 minutes with recovery occurring in approximately 60 minutes [
         <a href="#rid50">
          50
         </a>
         ]. Onset of action with IN midazolam administration is typically more rapid than oral administration but duration of sedation is shorter (20 to 30 minutes) [
         <a href="#rid51">
          51
         </a>
         ]. Due to the low pH and the benzyl alcohol preservative, IN midazolam can be irritating when administered. Pretreatment with
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         spray (10 mg per puff) one minute prior to IN midazolam administration decreases nasal mucosal irritation. An atomizer is preferred for the IN delivery of midazolam because of more reliable nasal mucosa absorption, better comfort, and reduction of sneezing and cough when compared with direct instillation [
         <a href="#rid51">
          51
         </a>
         ]. Although midazolam may be administered rectally, this route is less reliable.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         has good efficacy for nonpainful procedures that permit motion [
         <a href="#rid50">
          50,51
         </a>
         ] and has a shorter duration of action than oral or rectal
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         (&lt;1 hour versus 1 to 4 hours, respectively). Unlike barbiturates, midazolam is not associated with prolonged symptoms of ataxia, sleepiness, or irritability  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'No intravenous access'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13307" href="/z/d/drug information/13307.html" rel="external">
          Flumazenil
         </a>
         is an effective reversal agent for the few patients who develop significant respiratory depression or apnea after sedation with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         . Flumazenil should
         <strong>
          not
         </strong>
         be used in patients with seizure disorders or those who receive benzodiazepines on a chronic basis because of the risk of precipitating seizures or withdrawal symptoms, respectively. The use of flumazenil to reverse adverse effects of benzodiazepines, including dosing and re-dosing recommendations is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253094">
         <span class="h1">
          SEDATION FOR PAINFUL PROCEDURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians frequently employ procedural sedation for infants and children undergoing a variety of painful procedures including fracture reduction, laceration repair, bone marrow aspiration, central line placement, and lumbar puncture. For these procedures, chosen agents or combinations of agents must safely provide sedation
         <strong>
          and
         </strong>
         analgesia.
        </p>
        <p class="headingAnchor" id="H2253108">
         <span class="h2">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient factors (eg, last oral intake, urgency of the procedure, prior sedation experience, and comorbidities [eg, asthma, upper respiratory infection]) are key considerations for sedation strategies in children undergoing painful procedures and are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation", section on 'Pre-sedation evaluation'
         </a>
         .)
        </p>
        <p>
         In healthy infants and children, anticipated pain during the procedure is also an important determinant of the depth and type of sedation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimally painful procedures (eg, peripheral intravenous [IV] cannula insertion or laceration repair in regions of the body where occasional movement does not interfere with the procedure) – Minimal sedation, often best achieved with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         . (See
         <a class="local">
          'Minimally painful procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severely painful procedures (eg, fracture reduction) or laceration repair where movement will interfere significantly with performance of the procedure) – Deep sedation, typically reached with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone (brief procedures), ketamine combined with propofol, or propofol combined with
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         . The provider should be aware that any of these regimens can produce general anesthesia depending upon the initial dose and frequency of re-dosing. (See
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Effective local or regional anesthesia can often lower the amount of sedative agent needed to provide adequate sedation and increase the safety of the procedure.
        </p>
        <p>
         The need for supplementary analgesia varies by the agents used for sedation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         has both sedative and analgesic properties and can thus be used alone to provide sedation for moderate to severely painful procedures. However, for wound repair, local anesthetic (eg, topical lidocaine-epinephrine-tetracaine [LET] gel or infiltration of a local anesthetic) or a regional nerve block is also typically used, especially if the repair is estimated to take longer than 10 to 15 minutes. (See
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         and
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         do
         <strong>
          not
         </strong>
         have analgesic properties and should be combined with other analgesic agents. Although propofol is used alone for brief, painful procedures by some practitioners, the doses necessary to achieve adequate analgesia and control unwanted motion during the procedure may approach those used for general anesthesia. Propofol alone may be appropriate when local or regional anesthesia provides complete pain control. (See
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Although options vary, typical approaches to analgesia by type of procedure include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wound repair
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Topical anesthetic (eg, lidocaine-epinephrine-tetracaine) (see
         <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">
          "Clinical use of topical anesthetics in children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Local infiltration of anesthetic (see
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics", section on 'Procedure'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Regional anesthesia (eg, lacerations of the face, fingertip, distal toe, plantar foot, or penis) as described separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Facial lacerations (see
         <a class="medical medical_review" href="/z/d/html/13875.html" rel="external">
          "Assessment and management of facial lacerations", section on 'Facial nerve blocks'
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fingertip and distal toe (see
         <a class="medical medical_review" href="/z/d/html/262.html" rel="external">
          "Digital nerve block", section on 'Digital block procedures'
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Plantar foot (see
         <a class="medical medical_review" href="/z/d/html/100070.html" rel="external">
          "Lower extremity nerve blocks: Techniques", section on 'Ankle block'
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Penis (see
         <a class="medical medical_review" href="/z/d/html/6326.html" rel="external">
          "Management of zipper entrapment injuries", section on 'Dorsal penile block'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Closed reduction of fractures
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Opioid analgesia (eg,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         ; IV opioids have been associated with an increased risk of oxygen desaturation, vomiting, or need for positive-pressure ventilation, especially when administered less than 30 minutes prior to sedation) (see
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hematoma block (distal radial fractures) (see
         <a class="medical medical_review" href="/z/d/html/219.html" rel="external">
          "Distal radius fractures in adults", section on 'Performance of hematoma block'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bier block (fractures of the hand or forearm) (see
         <a class="medical medical_review" href="/z/d/html/399.html" rel="external">
          "Overview of anesthesia", section on 'Intravenous regional anesthesia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Regional anesthesia (eg, pain control for femoral fractures) (see
         <a class="medical medical_review" href="/z/d/html/100070.html" rel="external">
          "Lower extremity nerve blocks: Techniques"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lumbar puncture or bone marrow aspiration – Topical anesthetic followed by local infiltration of anesthetic (see
         <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">
          "Clinical use of topical anesthetics in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2253115">
         <span class="h3">
          Minimally painful procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many children undergoing IV cannula insertion or laceration repair, local anesthetics can be delivered topically or by direct infiltration to diminish or abolish the pain without the need for sedation, especially when age-appropriate nonpharmacologic interventions are used. (See
         <a class="local">
          'Nonpharmacologic interventions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">
          "Clinical use of topical anesthetics in children", section on 'Lidocaine-prilocaine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics"
         </a>
         .)
        </p>
        <p>
         When nonpharmacologic interventions and local anesthetics are
         <strong>
          not
         </strong>
         sufficient and minimal sedation is necessary for minimally painful procedures (eg, peripheral IV line placement, urethral catheterization, small laceration repair, or nasogastric tube placement), we suggest that healthy children (American Society of Anesthesiologists [ASA] class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) receive sedation with inhaled
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O); oral, sublingual, or intranasal (IN)
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ; or IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         rather than short-acting barbiturates  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). When N
         <sub>
          2
         </sub>
         O is available and tolerated by the patient, it is preferred to midazolam as summarized below. IN dexmedetomidine has been used for minimal sedation but requires more study before best practice guidelines for administration are determined.
        </p>
        <p>
         When compared with N
         <sub>
          2
         </sub>
         O, IN
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , or IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         , oral or rectal barbiturates are associated with higher rates of adverse effects, especially respiratory depression, (thiopental or
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) or prolonged duration of sedation (
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         )  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         – Because it has a shorter recovery time and fewer overall adverse effects, nitrous oxide (N
         <sub>
          2
         </sub>
         O)
         <sub>
         </sub>
         may be preferred to
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         in cooperative children for the following reasons [
         <a href="#rid52">
          52-55
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The onset of action is short (&lt;1 minute).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recovery is typically faster (&lt;20 minutes versus 30 to 60 minutes, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For selected procedures, N
         <sub>
          2
         </sub>
         O may also have greater efficacy. For example, in a trial, of over 250 children undergoing facial laceration repair, N
         <sub>
          2
         </sub>
         O or N
         <sub>
          2
         </sub>
         O combined with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         decreased distress to a greater extent than midazolam alone or
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         with comforting [
         <a href="#rid52">
          52
         </a>
         ]. In another trial of 90 children in whom IV access was expected to be difficult, use of N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         was associated with a significantly increased success rate for IV placement when compared with oral midazolam [
         <a href="#rid53">
          53
         </a>
         ]. Procedure time was also significantly shorter for patients who received 50 percent N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         when compared with oral midazolam.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adverse events following N
         <sub>
          2
         </sub>
         O use are typically self-limited with vomiting being most common (approximately 6 to 7 percent of patients, primarily those with longer duration of inhalation or who also received opioids) [
         <a href="#rid52">
          52,54-56
         </a>
         ]. Serious adverse effects (eg, postprocedure desaturation, apnea, stridor, aspiration, laryngospasm, or airway obstruction) are rare (eg, 0.2 percent in two observational studies and one case report of aspiration and laryngospasm) [
         <a href="#rid55">
          55-57
         </a>
         ]). Thus, N
         <sub>
          2
         </sub>
         O use requires the same level of preparation and vigilance as other sedative agents. (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Performing procedural sedation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The method for administering N
         <sub>
          2
         </sub>
         O for procedural sedation and additional precautions are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Nitrous oxide'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         – Based upon one large observational study, up to one-third of patients, especially children younger than 4 years of age, may
         <strong>
          not
         </strong>
         tolerate N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         delivery [
         <a href="#rid58">
          58
         </a>
         ]. Such patients are good candidates for oral or IN midazolam [
         <a href="#rid54">
          54
         </a>
         ]. Midazolam is also a reasonable alternative when N
         <sub>
          2
         </sub>
         O is not available. If the IN route of administration is chosen, pretreatment with
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         spray (10 mg per puff) one minute prior to administration and use of an atomizer is suggested [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         – Preliminary evidence suggests that IN dexmedetomidine may be equivalent to
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         for minimally painful procedures. As an example, in a trial of 40 young children (mean age three years) undergoing laceration repair, intranasal (IN) dexmedetomidine (2 mcg/kg) was similar to IN midazolam (0.4 mg/kg) for anxiolysis during repair but was associated with less anxiety during positioning with significantly more children showing no anxiety at this time point (70 versus 11 percent) [
         <a href="#rid48">
          48
         </a>
         ]. Although evidence for safety and efficacy for this specific use of IN dexmedetomidine in children is limited, results from small trials where IN dexmedetomidine was used for other purposes (eg, nonpainful procedures, dental procedures, or preoperative sedation) support safety and efficacy that is potentially equivalent to midazolam [
         <a href="#rid49">
          49,59-64
         </a>
         ]. Larger studies are needed to determine optimal dosing and to identify more infrequent side effects.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2253122">
         <span class="h3">
          Moderately or severely painful procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         For healthy infants and children (ASA class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ) who are undergoing moderately or severely painful procedures of short duration (eg, fracture reduction, bone marrow aspiration), we suggest procedural sedation with IV
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , ketamine combined with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         combined with propofol rather than opioids combined with benzodiazepines (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ) or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         . When ketamine is used, a prophylactic dose of
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         may reduce postprocedure vomiting. For selected procedures, effective regional anesthesia can reduce the required medication dose or eliminate the need for moderate or deep sedation altogether. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
         Dosing and administration of specific IV sedation drugs used for moderate, dissociative, or deep sedation are provided in the table  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents"
         </a>
         .)
        </p>
        <p>
         Based upon observational studies and randomized trials, similar sedation efficacy for moderate to severely painful procedures, such as fracture reduction or bone marrow aspiration, is achieved with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone, ketamine combined with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         combined with propofol [
         <a href="#rid65">
          65
         </a>
         ] compared with regimens that combine opioids (typically fentanyl) with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid66">
          66-68
         </a>
         ] or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         [
         <a href="#rid69">
          69,70
         </a>
         ]. All of the above IV regimens have a rapid onset of effect ranging from 30 seconds for etomidate and propofol to 1 to 2 minutes for ketamine alone or midazolam with fentanyl  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ). Recovery from sedation using ketamine alone or ketamine with propofol ranges from 15 to 30 minutes which is longer than for etomidate or propofol (5 to 15 minutes) but shorter than for midazolam with fentanyl (15 to 60 minutes). Providers using propofol should have specific training in the use of propofol and the provision of deep sedation or anesthesia [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         The IV regimens vary in terms of the frequency of important adverse events (see
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With recommended dosing,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         sedation tends to preserve airway reflexes and is associated with fewer airway or respiratory adverse events that require intervention than
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         . On the other hand, vomiting and agitation during emergence are more frequent following ketamine sedation than with the other regimens although avoidance of high dosing (≥2.5 mg/kg initial dose or total dose ≥5 mg/kg) may reduce the frequency of these adverse events [
         <a href="#rid72">
          72
         </a>
         ] and prophylactic
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         significantly reduces vomiting [
         <a href="#rid73">
          73
         </a>
         ]. Hypotension, which occurs frequently during sedation with propofol, is not described following ketamine sedation. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The combination of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         for procedural sedation appears to provide effective sedation and less vomiting than reported for ketamine alone and less hypotension than described with propofol alone. However, adverse respiratory events including laryngospasm can still occur [
         <a href="#rid74">
          74
         </a>
         ]. Suggested dosing for this regimen is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         is preferred by some sedation practitioners because it is equally efficacious to
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         or ketamine combined with propofol and may produce a shorter and smoother recovery [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         alone for these procedures is associated with high levels of responsiveness to pain (up to 40 percent of patients) and need for restraint (up to one-third of patients) and is
         <strong>
          not
         </strong>
         recommended [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Appropriate analgesia is an important adjunct to sedation that is frequently necessary for children undergoing moderate to severely painful procedures. However, administration of IV opioids prior to sedation is associated with increased frequency of oxygen desaturation, vomiting, and need for positive-pressure ventilation during sedation although the absolute effect on vomiting or the need for positive-pressure ventilation is small. The provider should anticipate and be prepared to manage these adverse events and, when possible, administer alternative, nonopioid analgesics, especially within 30 minutes prior to sedation. For example, in a prospective, multicenter, observational study of almost 6300 children undergoing sedation for painful procedures in the emergency department, opioid administration prior to the procedure versus no opioid analgesia was associated with an increased risk of oxygen desaturation (9 versus 4 percent), vomiting (7 versus 5 percent), and need for positive-pressure ventilation (1.5 versus 0.9 percent) [
         <a href="#rid76">
          76
         </a>
         ]. These risks were greatest when opioid analgesia was administered closer to the time of sedation (eg, less than 30 minutes). Compared with
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         was associated with decreased odds of oxygen desaturation (odds ratio [OR] 0.5, 95% CI 0.3-0.8) and vomiting (OR 0.5, 95% CI 0.34-0.95), but this finding requires confirmation in randomized trials.
        </p>
        <p class="headingAnchor" id="H4132725093">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126190.html" rel="external">
          "Society guideline links: Procedural sedation in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2255305">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topic
         </strong>
         <strong>
          scope
         </strong>
         – This topic provides guidance for emergency and scheduled (elective) pediatric procedural sedation performed by sedation providers from a variety of disciplines including general and pediatric emergency medicine, pediatric critical care medicine, pediatric hospital medicine, and general pediatrics. (See
         <a class="local">
          'Topic scope'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic interventions
         </strong>
         – Techniques such as distraction, desensitization, reinforcement of coping skills, positive reinforcement, and relaxation are complementary to pharmacologic interventions and, in some children, may prevent the need for sedation altogether. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of sedative agents
         </strong>
         – The targeted depth and the agents used for pediatric procedural sedation depend on (see
         <a class="local">
          'Choice of sedative agents'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The specific procedure, especially the anticipated degree of pain and length of the procedure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Allowable patient movement during the procedure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient factors, especially age/developmental level, degree of anxiety, ability to cooperate, fasting status, airway assessment, and ASA classification  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All drug combinations used to provide targeted deep sedation for painful procedures (eg,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone, propofol and
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         , propofol and
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) can result in general anesthesia depending upon the initial dose(s) and frequency of redosing. Providers must always be prepared to provide rescue interventions (eg, bag-mask ventilation for apnea) for these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – The safe performance of pediatric sedation requires proper selection and evaluation of patients, appropriate preparation, and the performance of sedation by providers with appropriate training and institutional support in accordance with guidelines designed to maximize patient safety. (See
         <a class="local">
          'Safety requirements'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Analgesia
         </strong>
         – Local or regional anesthesia and/ or opioid analgesia are important adjuncts for patient comfort and can decrease the depth or total dose of sedative needed to successfully complete the procedures. However, IV administration of opioids prior to sedation is associated with increased frequency of oxygen desaturation, vomiting, and need for positive-pressure ventilation during sedation and the provider should be prepared to manage these adverse events. (See
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – The properties of the specific agents and dosing for pediatric sedation are listed in the tables  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging studies
         </strong>
         – Imaging can often be performed
         <strong>
          without
         </strong>
         sedation in older cooperative children and young infants (up to six months of age) who are bundled and recently fed. When necessary, the selection of medications for these procedures are determined by the duration of the test and whether vascular access is present (see
         <a class="local">
          'Sedation for imaging studies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Noninterventional CT
         </strong>
         – For healthy infants and children (American Society of Anesthesiologists [ASA] class I or II  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         )) who have vascular access and are undergoing sedation for CT, we recommend IV bolus doses of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         rather than IV short-acting barbiturates (eg,
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) or
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). When used as a single agent, ketamine may be associated with random movement in some patients and may not be ideal. (See
         <a class="local">
          'Intravenous medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We prefer administration of IV medications, whenever possible, for uncooperative children undergoing CT. When an IV cannot be placed, medication options and route of administration include intramuscular (IM)
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , oral or intranasal (IN)
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , and IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         . However, successful completion of the procedure is lower than for IV agents. (See
         <a class="local">
          'No intravenous access'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MRI
         </strong>
         – For healthy infants and children (ASA class I or II) undergoing MRI, we suggest continuous IV infusion of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         and dexmedetomidine, or dexmedetomidine bolus followed by propofol sedation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Magnetic resonance imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other nonpainful diagnostic procedures
         </strong>
         – For healthy children undergoing minimal sedation for other nonpainful (eg, echocardiography or electroencephalogram), we suggest IN
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         rather than short-acting barbiturates (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While oral or sublingual midazolam may also be efficacious, longer onset of action and prolonged duration of action will limit its use in many settings.
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) is also a reasonable option when mask delivery is tolerated. (See
         <a class="local">
          'Sedation for other nonpainful procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimally painful procedures
         </strong>
         – When nonpharmacologic interventions and topical anesthetics are
         <strong>
          not
         </strong>
         sufficient and mild sedation is
        </p>
        <p class="bulletIndent1">
         necessary for minimally painful procedures (eg, IV cannula placement), we suggest that healthy children (ASA class I or II) receive inhaled
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O); oral, sublingual, or IN
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ; or IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). IV sedation as described for CT is suggested for patients who fail sedation with these agents. (See
         <a class="local">
          'Minimally painful procedures'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Nitrous oxide'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate or severely painful procedures
         </strong>
         – For healthy infants and children (ASA class I or II) who are undergoing moderately or severely painful procedures of short duration (eg, fracture reduction or bone marrow aspiration), we suggest IV
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         , ketamine and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , or propofol and
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         rather than opioids combined with benzodiazepines (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ) or
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). When ketamine is used, a prophylactic dose of
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         may reduce postprocedure vomiting. (See
         <a class="local">
          'Moderately or severely painful procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H759944839">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Deborah C Hsu, MD, MEd, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coté CJ, Wilson S, AMERICAN ACADEMY OF PEDIATRICS, AMERICAN ACADEMY OF PEDIATRIC DENTISTRY. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures. Pediatrics 2019; 143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu X, McCullough WP, Mecca P, et al. Dual-energy compared to single-energy CT in pediatric imaging: a phantom study for DECT clinical guidance. Pediatr Radiol 2016; 46:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cravero JP, Blike GT, Beach M, et al. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006; 118:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macias CG, Chumpitazi CE. Sedation and anesthesia for CT: emerging issues for providing high-quality care. Pediatr Radiol 2011; 41 Suppl 2:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacchetti A, Carraccio C, Giardino A, Harris RH. Sedation for pediatric CT scanning: is radiology becoming a drug-free zone? Pediatr Emerg Care 2005; 21:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutman MS. Sedation for emergent diagnostic imaging studies in pediatric patients. Curr Opin Pediatr 2009; 21:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxter AL, Mallory MD, Spandorfer PR, et al. Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium. Pediatr Emerg Care 2007; 23:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kienstra AJ, Ward MA, Sasan F, et al. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. Pediatr Emerg Care 2004; 20:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Prescilla R, Fontaine PJ, Zurakowski D. Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital. AJR Am J Roentgenol 2011; 196:W194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth 2008; 18:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan M, Turmelle M, Depalma LM, et al. Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions. J Pediatr 2012; 160:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunwell JR, Travers C, McCracken CE, et al. Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium. Pediatr Crit Care Med 2016; 17:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh R, Kumar N, Vajifdar H. Midazolam as a sole sedative for computed tomography imaging in pediatric patients. Paediatr Anaesth 2009; 19:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Agostino J, Terndrup TE. Chloral hydrate versus midazolam for sedation of children for neuroimaging: a randomized clinical trial. Pediatr Emerg Care 2000; 16:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harcke HT, Grissom LE, Meister MA. Sedation in pediatric imaging using intranasal midazolam. Pediatr Radiol 1995; 25:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chokshi AA, Patel VR, Chauhan PR, et al. Evaluation of intranasal Midazolam spray as a sedative in pediatric patients for radiological imaging procedures. Anesth Essays Res 2013; 7:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein EJ, Brown JC, Kobayashi A, et al. A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam. Ann Emerg Med 2011; 58:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghai B, Jain K, Saxena AK, et al. Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: a randomized, double-blind, and controlled study. Paediatr Anaesth 2017; 27:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuen VM, Li BL, Cheuk DK, et al. A randomised controlled trial of oral chloral hydrate vs. intranasal dexmedetomidine before computerised tomography in children. Anaesthesia 2017; 72:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rooks VJ, Chung T, Connor L, et al. Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results. AJR Am J Roentgenol 2003; 180:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Connor L, et al. Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital. Radiology 2004; 233:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Sanborn P, Zurakowski D, et al. Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging. Radiology 2004; 230:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomeranz ES, Chudnofsky CR, Deegan TJ, et al. Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients. Pediatrics 2000; 105:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glasier CM, Stark JE, Brown R, et al. Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies. AJNR Am J Neuroradiol 1995; 16:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway A, Rolley J, Sutherland JR. Midazolam for sedation before procedures. Cochrane Database Syst Rev 2016; :CD009491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahyoun C, Krauss B. Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children. Curr Opin Pediatr 2012; 24:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Academy of Pediatrics Committee on Drugs and Committee on Environmental Health: Use of chloral hydrate for sedation in children. Pediatrics 1993; 92:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heard C, Burrows F, Johnson K, et al. A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging. Anesth Analg 2008; 107:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Gunter J, Donnelly LF, et al. A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children. Anesth Analg 2009; 109:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth 2010; 20:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008; 18:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol 2009; 41:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dave J, Vaghela S. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Saudi J Anaesth 2011; 5:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teshome G, Belani K, Braun JL, et al. Comparison of dexmedetomidine with pentobarbital for pediatric MRI sedation. Hosp Pediatr 2014; 4:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boriosi JP, Eickhoff JC, Klein KB, Hollman GA. A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation. Paediatr Anaesth 2017; 27:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagoshi M, Reddy S, Bell M, et al. Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: A double-cohort study. Paediatr Anaesth 2018; 28:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortellazzi P, Lamperti M, Minati L, et al. Sedation of neurologically impaired children undergoing MRI: a sequential approach. Paediatr Anaesth 2007; 17:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vade A, Sukhani R, Dolenga M, Habisohn-Schuck C. Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines. AJR Am J Roentgenol 1995; 165:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallory MD, Baxter AL, Kost SI, Pediatric Sedation Research Consortium. Propofol vs pentobarbital for sedation of children undergoing magnetic resonance imaging: results from the Pediatric Sedation Research Consortium. Paediatr Anaesth 2009; 19:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado J, Toro R, Rascovsky S, et al. Chloral hydrate in pediatric magnetic resonance imaging: evaluation of a 10-year sedation experience administered by radiologists. Pediatr Radiol 2015; 45:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang F, Liu Y, Yu Q, et al. Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine. Paediatr Anaesth 2019; 29:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Du M, Liu L, et al. Sedation effects of intranasal dexmedetomidine combined with ketamine and risk factors for sedation failure in young children during transthoracic echocardiography. Paediatr Anaesth 2019; 29:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMorrow SP, Abramo TJ. Dexmedetomidine sedation: uses in pediatric procedural sedation outside the operating room. Pediatr Emerg Care 2012; 28:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zub D, Berkenbosch JW, Tobias JD. Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication. Paediatr Anaesth 2005; 15:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakurai Y, Obata T, Odaka A, et al. Buccal administration of dexmedetomidine as a preanesthetic in children. J Anesth 2010; 24:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neville DN, Hayes KR, Ivan Y, et al. Double-blind Randomized Controlled Trial of Intranasal Dexmedetomidine Versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department. Acad Emerg Med 2016; 23:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poonai N, Spohn J, Vandermeer B, et al. Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review. Pediatrics 2020; 145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Layangool T, Sangtawesin C, Kirawittaya T, et al. A comparison of oral chloral hydrate and sublingual midazolam sedation for echocardiogram in children. J Med Assoc Thai 2008; 91 Suppl 3:S45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaretti A, Barone G, Rigante D, et al. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child 2011; 96:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luhmann JD, Kennedy RM, Porter FL, et al. A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 2001; 37:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekbom K, Kalman S, Jakobsson J, Marcus C. Efficient intravenous access without distress: a double-blind randomized study of midazolam and nitrous oxide in children and adolescents. Arch Pediatr Adolesc Med 2011; 165:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zier JL, Liu M. Safety of high-concentration nitrous oxide by nasal mask for pediatric procedural sedation: experience with 7802 cases. Pediatr Emerg Care 2011; 27:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babl FE, Oakley E, Seaman C, et al. High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation. Pediatrics 2008; 121:e528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsze DS, Mallory MD, Cravero JP. Practice Patterns and Adverse Events of Nitrous Oxide Sedation and Analgesia: A Report from the Pediatric Sedation Research Consortium. J Pediatr 2016; 169:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babl FE, Grindlay J, Barrett MJ. Laryngospasm With Apparent Aspiration During Sedation With Nitrous Oxide. Ann Emerg Med 2015; 66:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annequin D, Carbajal R, Chauvin P, et al. Fixed 50% nitrous oxide oxygen mixture for painful procedures: A French survey. Pediatrics 2000; 105:E47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds J, Rogers A, Medellin E, et al. A prospective, randomized, double-blind trial of intranasal dexmedetomidine and oral chloral hydrate for sedated auditory brainstem response (ABR) testing. Paediatr Anaesth 2016; 26:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gumus H, Bayram AK, Poyrazoglu HG, et al. Comparison of Effects of Different Dexmedetomidine and Chloral Hydrate Doses Used in Sedation on Electroencephalography in Pediatric Patients. J Child Neurol 2015; 30:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surendar MN, Pandey RK, Saksena AK, et al. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. J Clin Pediatr Dent 2014; 38:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth 2014; 24:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SS, Zhang MZ, Sun Y, et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. Paediatr Anaesth 2014; 24:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talon MD, Woodson LC, Sherwood ER, et al. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res 2009; 30:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godambe SA, Elliot V, Matheny D, Pershad J. Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department. Pediatrics 2003; 112:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migita RT, Klein EJ, Garrison MM. Sedation and analgesia for pediatric fracture reduction in the emergency department: a systematic review. Arch Pediatr Adolesc Med 2006; 160:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy RM, Porter FL, Miller JP, Jaffe DM. Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics 1998; 102:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. Acad Emerg Med 2005; 12:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Liddo L, D'Angelo A, Nguyen B, et al. Etomidate versus midazolam for procedural sedation in pediatric outpatients: a randomized controlled trial. Ann Emerg Med 2006; 48:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandt MJ, Roback MG, Bajaj L, et al. Etomidate for short pediatric procedures in the emergency department. Pediatr Emerg Care 2012; 28:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallory MD, Baxter AL, Yanosky DJ, et al. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium. Ann Emerg Med 2011; 57:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Krauss B, et al. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009; 54:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langston WT, Wathen JE, Roback MG, Bajaj L. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 2008; 52:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunwell JR, Travers C, Stormorken AG, et al. Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium. Pediatr Crit Care Med 2017; 18:e356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cravero JP, Beach ML, Blike GT, et al. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg 2009; 108:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt M, Cheng W, Roback MG, et al. Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation. Acad Emerg Med 2020; 27:217.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 85542 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16517277" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Procedural sedation and analgesia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31138666" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27518078" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dual-energy compared to single-energy CT in pediatric imaging: a phantom study for DECT clinical guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951002" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21847733" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sedation and anesthesia for CT: emerging issues for providing high-quality care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15874810" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sedation for pediatric CT scanning: is radiology becoming a drug-free zone?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19381092" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sedation for emergent diagnostic imaging studies in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18090099" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295244" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257862" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363628" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hemodynamic effects of dexmedetomidine sedation for CT imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177990" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27505716" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19619188" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Midazolam as a sole sedative for computed tomography imaging in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699144" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10698133" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chloral hydrate versus midazolam for sedation of children for neuroimaging: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7567258" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sedation in pediatric imaging using intranasal midazolam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25885831" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Evaluation of intranasal Midazolam spray as a sedative in pediatric patients for radiological imaging procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21689865" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27734549" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: a randomized, double-blind, and controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28741653" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A randomised controlled trial of oral chloral hydrate vs. intranasal dexmedetomidine before computerised tomography in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12646468" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516603" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699175" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10790471" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900578" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27198122" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Midazolam for sedation before procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22245909" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8361811" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : American Academy of Pediatrics Committee on Drugs and Committee on Environmental Health: Use of chloral hydrate for sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020127" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19690241" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20412458" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363626" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : High dose dexmedetomidine as the sole sedative for pediatric MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589455" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Dexmedetomidine for procedural sedation in children with autism and other behavior disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21957410" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25362077" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparison of dexmedetomidine with pentobarbital for pediatric MRI sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27779360" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29882298" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: A double-cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17564644" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sedation of neurologically impaired children undergoing MRI: a sequential approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7676990" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19645979" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Propofol vs pentobarbital for sedation of children undergoing magnetic resonance imaging: results from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25142238" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chloral hydrate in pediatric magnetic resonance imaging: evaluation of a 10-year sedation experience administered by radiologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30484930" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30450703" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Sedation effects of intranasal dexmedetomidine combined with ketamine and risk factors for sedation failure in young children during transthoracic echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391930" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Dexmedetomidine sedation: uses in pediatric procedural sedation outside the operating room.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16238552" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20175284" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Buccal administration of dexmedetomidine as a preanesthetic in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27129606" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Double-blind Randomized Controlled Trial of Intranasal Dexmedetomidine Versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31862730" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255992" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A comparison of oral chloral hydrate and sublingual midazolam sedation for echocardiogram in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21030365" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Intranasal lidocaine and midazolam for procedural sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11145766" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536947" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficient intravenous access without distress: a double-blind randomized study of midazolam and nitrous oxide in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22134227" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Safety of high-concentration nitrous oxide by nasal mask for pediatric procedural sedation: experience with 7802 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18310173" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26547401" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Practice Patterns and Adverse Events of Nitrous Oxide Sedation and Analgesia: A Report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26003005" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Laryngospasm With Apparent Aspiration During Sedation With Nitrous Oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10742368" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Fixed 50% nitrous oxide oxygen mixture for painful procedures: A French survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26814038" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A prospective, randomized, double-blind trial of intranasal dexmedetomidine and oral chloral hydrate for sedated auditory brainstem response (ABR) testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25246305" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Comparison of Effects of Different Dexmedetomidine and Chloral Hydrate Doses Used in Sedation on Electroencephalography in Pediatric Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25095322" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24237879" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24224515" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506498" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837876" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389210" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Sedation and analgesia for pediatric fracture reduction in the emergency department: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9755272" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15930401" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997680" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Etomidate versus midazolam for procedural sedation in pediatric outpatients: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22929142" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Etomidate for short pediatric procedures in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21513827" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19201064" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18353503" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650904" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224786" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31894606" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
